This Research Topic is a second volume. Please see the first volume at: Neoadjuvant Therapy in Non-Small Cell Lung Cancer: Clinical, Pathological and Translational ResearchPatients with resectable non-small cell lung cancer (NSCLC) are often treated with surgery and adjuvant therapy. However, these patients continue to have a high risk of recurrence and death. So far, neoadjuvant therapy, defined as anticancer treatment given before surgery, has been considered as an approach that could potentially improve survival in patients with resected NSCLC. Potential advantages of neoadjuvant therapy include early treatment of micrometastasis, reducing tumor burden before surgery, and better tolerability, have been well established. More importantly, multiple neoadjuvant trials with immunotherapy and targeted therapy, either alone or in combination with chemotherapy, have shed new light on the long-term survival of patients with resected NSCLC, yielded unique insights into traditional response parameters, and expanded opportunities for biomarker discovery. Thus, encouraged by the need to improve survival outcomes in early-stage NSCLC, there has been intense interest in revisiting and optimizing neoadjuvant strategies from the clinical, pathological and translational perspectives.
This Research Topic aims to provide an update on the current neoadjuvant treatment strategies, discuss the rationale for neoadjuvant therapy, evaluate the benefits and limitations of the available neoadjuvant therapy, and consider surgical challenges and technical aspects after neoadjuvant therapy in patients with resectable lung cancer.
We welcome original research, cutting-edge reviews, clinical, pathological, and translational studies related but not limited to the following:
• Clinical studies illustrating the efficacy and safety of neoadjuvant therapy in NSCLC
• New neoadjuvant treatment strategies in NSCLC
• Technical advances in surgery for NSCLC after neoadjuvant therapy
• Pathological and molecular features of NSCLC after neoadjuvant therapy
• Prediction models for pathologic response in NSCLC patients with neoadjuvant therapy based on radiomic analysis
• New biomarkers to guide and monitor neoadjuvant treatment in NSCLC
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
